Due to high levels of NDMA found in Zantac, over exposure to the medication can lead to an increased risk of cancer in humans.
Please contact your health care professional immediately if you believe you’ve been exposed to high levels of NDMA. The levels of NDMA found in Zantac vary, but may increase based on the products age and exposure to higher than the recommended storage temperatures.
Gastrointestinal cancer can refer to anything within the GI tract. This include any organs that help with digestion such as the stomach, biliary system, pancreas, small intestine, large intestine, rectum and anus.
Esophageal Cancer is found in the esophagus. Signs and symptoms of esophageal cancer are weight loss and painful or difficult swallowing.
Colorectal cancer is cancer located in the colon (large intestine) or rectum, at the end of the digestive tract. This cancer is also known as bowel cancer, colon cancer, or rectal cancer.
Liver cancer is a type of cancer that begins in the cells of the liver. Liver cancer includes hepatocellular carcinoma (HCC) and bile duct cancer (cholangiocarcinoma).
High levels of NDMA exposure from ranitidine or Zantac medication has also been linked to other cancers such as:
FAQs about the Zantac Recall
Important questions and answers regarding the recent Zantac recall and the potential risk of cancer from high levels of NDMA.
Zantac (Ranitidine) Medication Recall
The U.S. Food and Drug Administration announces the recall of all prescription and over-the-counter ranitidine medications.